- Home
- ACIU vs GOSS Comparison
ACIU vs GOSS Comparison
Compare ACIU & GOSS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACIU
- GOSS
- Stock Information
- Founded
- ACIU 2003
- GOSS 2015
- Country
- ACIU Switzerland
- GOSS United States
- Employees
- ACIU N/A
- GOSS N/A
- Industry
- ACIU Biotechnology: Pharmaceutical Preparations
- GOSS Biotechnology: Pharmaceutical Preparations
- Sector
- ACIU Health Care
- GOSS Health Care
- Exchange
- ACIU Nasdaq
- GOSS Nasdaq
- Market Cap
- ACIU 173.7M
- GOSS 203.3M
- IPO Year
- ACIU 2016
- GOSS 2019
- Fundamental
- Price
- ACIU $1.69
- GOSS $1.11
- Analyst Decision
- ACIU Strong Buy
- GOSS Strong Buy
- Analyst Count
- ACIU 2
- GOSS 4
- Target Price
- ACIU $10.00
- GOSS $7.50
- AVG Volume (30 Days)
- ACIU 137.1K
- GOSS 1.6M
- Earning Date
- ACIU 04-30-2025
- GOSS 05-13-2025
- Dividend Yield
- ACIU N/A
- GOSS N/A
- EPS Growth
- ACIU N/A
- GOSS N/A
- EPS
- ACIU N/A
- GOSS N/A
- Revenue
- ACIU $32,014,254.00
- GOSS $114,701,000.00
- Revenue This Year
- ACIU N/A
- GOSS N/A
- Revenue Next Year
- ACIU $676.94
- GOSS $172.31
- P/E Ratio
- ACIU N/A
- GOSS N/A
- Revenue Growth
- ACIU 91.20
- GOSS N/A
- 52 Week Low
- ACIU $1.43
- GOSS $0.50
- 52 Week High
- ACIU $4.98
- GOSS $1.55
- Technical
- Relative Strength Index (RSI)
- ACIU 46.75
- GOSS 55.89
- Support Level
- ACIU $1.55
- GOSS $1.06
- Resistance Level
- ACIU $1.79
- GOSS $1.26
- Average True Range (ATR)
- ACIU 0.10
- GOSS 0.11
- MACD
- ACIU 0.03
- GOSS 0.03
- Stochastic Oscillator
- ACIU 66.67
- GOSS 68.18
About ACIU AC Immune SA
AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The Company has one segment. The Company currently focuses most of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.
About GOSS Gossamer Bio Inc.
Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.